We are live on ! Find out more
CAI icon

Caris Life Sciences

140 hedge funds and large institutions have $3.42B invested in Caris Life Sciences in 2025 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 46 increasing their positions, 19 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

649% more call options, than puts

Call options by funds: $12.3M | Put options by funds: $1.64M

142% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 19

77% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 30

75% more capital inflows, than outflows

Capital inflows: $362M | Capital outflows: $207M

20% more funds holding

Funds holding: 117 → 140 (+23)

1.9% more ownership

Funds ownership: 38.56% → 40.46% (+1.9%)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

Holders
140
Holders Change
+23
Holders Change %
+19.66%
% of All Funds
1.83%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
53
Increased
46
Reduced
19
Closed
30
Calls
$12.3​M
Puts
$1.64​M
Net Calls
+$10.7​M
Net Calls Change
+$12.7​M

CAI Hedge Fund Activity: Q3 2025 in Review

140 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Caris Life Sciences (CAI) for Q3 2025, worth a combined $3.42B — up 17% from $2.92B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new CAI positions and 30 closed out — a net gain of 23 holders — while 46 added to existing stakes and 19 trimmed.

The largest buyer was PointState Capital, adding an estimated $44.2M. The largest seller was Neuberger Berman Group, cutting an estimated $60.4M.

  • 140 institutional investors held Caris Life Sciences (CAI) as of Q3 2025, up from 117 in Q2 2025.
  • Funds reported $3.42B of Caris Life Sciences stock for Q3 2025, up 17% quarter-over-quarter.
  • 53 funds opened new Caris Life Sciences positions in Q3 2025 and 30 closed out, a net change of +23 holders.
  • The largest Caris Life Sciences buyer in Q3 2025 was PointState Capital, an estimated $44.2M added.
  • The largest Caris Life Sciences seller in Q3 2025 was Neuberger Berman Group, an estimated $60.4M sold.

Based on aggregated 13F filings for Q3 2025.